These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 4681847)

  • 21. Effect of 3-[4-amino-2-methyl-5-pyrimidinyl)ethyl[-1(2-chloroethyl)-1-nitrosourea hydrochloride on lymphoid leukemia L-1210.
    Shimizu F; Arakawa M
    Gan; 1975 Apr; 66(2):149-54. PubMed ID: 1150007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined chronochemotherapy of L1210 leukemic mice using 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine, methylprednisolone and cis-diamminedichloroplatinum.
    Scheving LE; Burns ER; Halberg F; Pauly JE
    Chronobiologia; 1980; 7(1):33-40. PubMed ID: 7192203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor activities of 3-(methyl-alpha-D-glucopyranos-6-YL)-1-(2-chloroethyl)-1-nitrosourea.
    Iwasaki M; Sekido S; Ninomiya K; Sekine J; Ueno S
    Gan; 1976 Feb; 67(1):137-9. PubMed ID: 1269854
    [No Abstract]   [Full Text] [Related]  

  • 24. Value of cytosine arabinoside (NSC-63878) plus 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) therapy in advanced murine L1210 leukemia and enhancement of the combination with sequential doses of methotrexate (NSC-740) or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
    Kline I; Woodman RJ; Gang M; Cysyk RL; Venditti JM
    Cancer Chemother Rep; 1973; 57(3):291-8. PubMed ID: 4751255
    [No Abstract]   [Full Text] [Related]  

  • 25. Enhancement of antitumor effectiveness of ICRF-159 (NSC-129943) against early L1210 leukemia by combination with cis-diamminedichloroplatinum (NSC-119875) or daunomycin (NSC-82151).
    Woodman RJ
    Cancer Chemother Rep 2; 1974 Mar; 4(1):45-52. PubMed ID: 4826499
    [No Abstract]   [Full Text] [Related]  

  • 26. Antitumour activity of a new water-soluble nitrosoureido sugar: CY233 (NSC 609224).
    Gosse C; Atassi G; Letourneux Y; Ardouin P; Gouyette A; Fournier JP; Roger P
    Anticancer Res; 1988; 8(6):1419-22. PubMed ID: 3218975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Experimental studies on oral administration of nitrosourea anti-tumor agent, MCNU].
    Sekido S; Ninomiya K; Araki T; Ueno M; Kinbara M
    Gan To Kagaku Ryoho; 1984 Jul; 11(7):1492-500. PubMed ID: 6234861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of liposome type and route of administration in the antitumor activity of liposome-entrapped 1-beta-D-arabinofuranosylcytosine against mouse L1210 leukemia.
    Rustum YM; Dave C; Mayhew E; Papahadjopoulos D
    Cancer Res; 1979 Apr; 39(4):1390-5. PubMed ID: 421223
    [No Abstract]   [Full Text] [Related]  

  • 29. Effects of 4,4'-diacetyl-diphenyl-urea-bis(guanylhydrazone) on leukemia L1210.
    Mihich E; Mulhern AI
    Cancer Res; 1968 Feb; 28(2):354-62. PubMed ID: 5641525
    [No Abstract]   [Full Text] [Related]  

  • 30. Hypothetical mechanism of therapeutic synergism induced by the combination of 6-thioguanine and 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride.
    Fujimoto S; Ogawa M; Sakurai Y
    Cancer Res; 1982 Oct; 42(10):4079-85. PubMed ID: 6955008
    [No Abstract]   [Full Text] [Related]  

  • 31. Combination chemotherapy in sequence for the treatment of L1210 leukemia.
    Roberts D; Hilliard SL
    Cancer Res; 1978 Aug; 38(8):2317-20. PubMed ID: 667827
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparison of mutagenicity, antitumor activity, and chemical properties of selected nitrosoureas and nitrosoamides.
    Brundrett RB; Colvin M; White EH; McKee J; Hartman PE; Brown DL
    Cancer Res; 1979 Apr; 39(4):1328-33. PubMed ID: 421216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased lifespan using the priming dose schedule design in carbazilquinone (NSC-134679) treatment of mouse leukemia L1210.
    Straus MJ; Goldin A
    Cancer Chemother Rep; 1972 Feb; 56(1):19-23. PubMed ID: 5030804
    [No Abstract]   [Full Text] [Related]  

  • 34. [Effect of combination chemotherapy of nitrosourea MCNU with various anti-tumor agents].
    Ninomiya K; Sekido S; Araki T
    Gan To Kagaku Ryoho; 1984 Jun; 11(6):1315-23. PubMed ID: 6428326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor effect and mode of action of 1-beta-D-arabinofuranosylcytosine 5'-phosphate in leukemia L1210.
    Schrecker AW; Goldin A
    Cancer Res; 1968 Apr; 28(4):802-3. PubMed ID: 5649067
    [No Abstract]   [Full Text] [Related]  

  • 36. Alterations in the toxicity and antitumor activity of methyl-CCNU in mice following pretreatment with either phenobarbital or SKF 525A.
    Klubes P; Miller HG; Cerna I; Trevithick J
    Cancer Treat Rep; 1979; 63(11-12):1901-7. PubMed ID: 526922
    [No Abstract]   [Full Text] [Related]  

  • 37. Biochemical aspects of drug combinations.
    Brockman RW
    Cancer Chemother Rep 2; 1974 Mar; 4(1):115-29. PubMed ID: 4135108
    [No Abstract]   [Full Text] [Related]  

  • 38. Synthesis and antitumour activity of 4-nitroso-4-(2-chloroethyl)semicarbazides.
    Gugova RG; Raikov ZD; Zakhariev SG; Demirov GD; Todorov DK; Ilarionova MV
    Drugs Exp Clin Res; 1989; 15(10):497-500. PubMed ID: 2632217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.
    Griswold DP; Trader MW; Frei E; Peters WP; Wolpert MK; Laster WR
    Cancer Res; 1987 May; 47(9):2323-7. PubMed ID: 3567926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and antitumour activity of several new 4-aroyl-1-nitrosohydrazinecarboxamides.
    Gugova R; Topakbashian V; Lozeva S; Dimov S; Golovinsky E
    Drugs Exp Clin Res; 1997; 23(2):71-5. PubMed ID: 9309382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.